This month we would like to introduce you to our Executive Chairman Christopher Getley.
A BIT ABOUT Christopher
After graduating with a Combined Hons Degree in Chemistry and Law from Exeter University Christopher spent 28 years in the investment industry as a Director of Morgan Grenfell Asset Management, Partner of Cazenove & Co and latterly as CEO of Westhouse Securities. In addition to his role at AgPlus Christopher is Non Executive Chairman of Masawara PLC, a Southern Africa focussed investment company and a Non Executive Director of Majedie Investments PLC, an investment trust.
Promoting consistently the AgPlus vision and values in order to grow the company for the benefit of patients, partners, staff, suppliers, shareholders and the wider community is the purpose of the Chairman. Supporting the team and ensuring the resources to grow the business are in place when required are the principal elements of the role. Alongside that is working with the CEO and Board to set and communicate a clear strategy that is both ambitious and achievable. Regular tasks include capital raising, developing key relationships and working to ensure that external and internal expectations are aligned as closely as possible.
STARTING WITH AG+
In early 2015 a senior executive at Serco Group, managers of the UK’s National Physical Laboratory which invented and patented the core AgPlus measurement technology, alerted me to a potential opportunity to buy the business. The team that came together to review and eventually complete the transaction have been fantastic in their consistent support.
BEST PART OF THE JOB
Working with such an innovative and determined team! Whilst the science behind the intellectual property at AgPlus gives huge competitive advantage it would come to nought without a strong team who are so clear in their aim to make lives better by matching each patient’s critical condition to the right treatment at the right time.
WORST PART OF THE JOB
Saying ‘no’ to spending plans.
THE YEAR AHEAD
Welcoming the final Agilis reader and cartridge products from the suppliers through this summer, verification of the platform in the autumn before delivery to the first B2B customers this winter are all exciting milestones ahead. COVID-19 has shown the importance of and requirement for rapid, accurate, near patient testing such as the AgPlus Agilis platform. The whole team at AgPlus look forward to demonstrating that commercially over every one of the next twelve months.
If you'd like to get in touch with Christopher directly, please call +44 (0) 1234867100 or click here to email.